サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1458700

非注射インスリンの世界市場レポート 2024年

Non-injectable Insulin Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非注射インスリンの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

非注射インスリンの市場規模は今後数年で急成長が見込まれます。2028年にはCAGR10.7％で28億9,000万米ドルに成長します。予測期間中に予測される成長は、患者のコンプライアンス重視の継続、注射針恐怖症に対するソリューションの開発、QOL向上への継続的な取り組み、安全対策の継続的強化、感染・傷害リスクの低減に起因しています。この期間に予想される主な動向には、技術の進歩、技術的ソリューションの進化、デジタルヘルス技術の統合、ナノテクノロジーの応用、併用療法の開発などが含まれます。これらの動向は、進化する患者のニーズに応え、治療成果を向上させるためのイノベーションとヘルスケアソリューションの進歩に焦点を当てたダイナミックな状況を浮き彫りにしています。

肥満と糖尿病の有病率の増加は、非注射インスリン市場の成長を牽引すると予想されます。カロリー摂取量とエネルギー消費量の不均衡による過剰な体脂肪を特徴とする肥満と、高血糖値を特徴とする代謝疾患群である糖尿病は、この動向に寄与する主な要因です。非注射インスリンは、インスリン治療への障壁を克服し、体重管理を助ける可能性があり、より便利な治療オプションを提供することにより、これらの状態を管理するための有望な解決策を提供します。例えば、世界心臓連盟は、世界の肥満率が2021年の23億人から2025年には27億人に増加すると予測しています。さらに、英国糖尿病協会の報告によると、英国では430万人が糖尿病を患っており、240万人以上が2型糖尿病を発症するリスクが高いです。この動向は、2021-22年の登録者数が前年比148,951人増であることによって、さらに強調されています。このように、非注射インスリン市場は、肥満と糖尿病という課題の深刻化により、大きな成長が見込まれています。

非注射インスリン市場の主要企業は、複数のインスリン注射で糖尿病を管理する人々の生活を向上させるため、針のない経口インスリン・スプレーなどの革新的なドラッグデリバリー技術に注力しています。針のないインスリン・スプレーは、血糖値を調整するための痛みのない代替手段を提供し、服用量を直接口に噴霧できるようにすることで、便利な選択肢を提供します。例えば、NiedlFree Technologies社は2023年11月に経口インスリン・スプレーであるOzulinを発表しました。オズリンは、糖尿病患者、特に従来のインスリン注射法に苦労している患者にとって、使いやすいソリューションを提供することを目指しています。承認されれば、オズリンはインスリン注射に代わる、より便利で苦痛のない方法を提供することで、糖尿病管理に革命をもたらす可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19感染症による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の非注射インスリン市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 合成インスリン
  • 半合成インスリン
  • 世界の非注射インスリン市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 丸薬
  • スプレー
  • その他の製品
  • 世界の非注射インスリン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • ドラッグストア

第7章 地域および国の分析

  • 世界の非注射インスリン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の非注射インスリン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 非注射インスリン市場の競合情勢
  • 非注射インスリン市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Abbott Laboratories
  • GlaxoSmithKline
  • Takeda Pharmaceutical
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Ipsen SA
  • Cadila Healthcare Limited
  • Dr. Reddy's Laboratories Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r16682

Non-injectable insulin, a type of insulin that doesn't require injection for administration, presents an innovative approach to diabetes management, aiming to enhance convenience and patient compliance. These non-injectable forms of insulin offer alternatives to traditional injections, potentially improving the overall quality of life for individuals with diabetes. They come in various forms, such as pills, sprays, and other delivery mechanisms, providing flexibility and ease of use for patients.

Synthetic insulin and semi-synthetic insulin are the two primary types of non-injectable insulin. Synthetic insulin is artificially produced through biotechnological methods, offering precise control over its composition and properties. This type of insulin can be tailored to meet specific patient needs and preferences. Semi-synthetic insulin is derived from natural sources but undergoes chemical modifications to enhance its stability, efficacy, or other desirable characteristics. Non-injectable insulin products are distributed through various channels, including hospital pharmacies, online pharmacies, and drug stores, ensuring accessibility for patients worldwide. These innovative insulin formulations represent a significant advancement in diabetes care, providing patients with additional options for managing their condition effectively while reducing the burden of frequent injections.

The non-injectable insulin market research report is one of a series of new reports from The Business Research Company that provides non-injectable insulin market statistics, including non-injectable insulin industry global market size, regional shares, competitors with a non-injectable insulin market share, detailed non-injectable insulin market segments, market trends and opportunities, and any further data you may need to thrive in the non-injectable insulin industry. This non-injectable insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-injectable insulin market size has grown rapidly in recent years. It will grow from $1.71 billion in 2023 to $1.92 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth observed in the historic period can be attributed to several factors, including improvements in patient compliance, efforts to address needle phobia, enhancements in quality of life, the ease of administration, and the achievement of stable blood glucose control.

The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The projected growth in the forecast period can be attributed to the ongoing emphasis on patient compliance, the development of solutions for needle phobia, continuous efforts to improve quality of life, ongoing enhancements in safety measures, and the reduction of infection and injury risks. Major trends expected during this period encompass technological advancements, the evolution of technological solutions, the integration of digital health technologies, the application of nanotechnology, and the development of combination therapies. These trends highlight a dynamic landscape focused on innovation and the advancement of healthcare solutions to meet evolving patient needs and improve treatment outcomes.

The increasing prevalence of obesity and diabetes is expected to drive the growth of the non-injectable insulin market. Obesity, characterized by excess body fat due to an imbalance between calorie intake and energy expenditure, and diabetes mellitus, a group of metabolic disorders marked by high blood sugar levels, are key factors contributing to this trend. Non-injectable insulin offers a promising solution for managing these conditions by overcoming barriers to insulin therapy, potentially aiding in weight management, and providing more convenient treatment options. For example, the World Heart Federation projects a rise in global obesity rates from 2.3 billion in 2021 to 2.7 billion by 2025. Additionally, a report by the British Diabetic Association indicates that in the UK, 4.3 million individuals have diabetes, with over 2.4 million at high risk of developing type 2 diabetes. This trend is further underscored by a 148,951 increase in registration numbers for 2021-22 compared to the previous year. As such, the non-injectable insulin market is poised for significant growth due to the escalating challenges of obesity and diabetes.

Major companies in the non-injectable insulin market are focusing on innovative drug delivery technologies, such as needle-free oral insulin sprays, to enhance the lives of individuals managing diabetes with multiple insulin injections. Needle-free insulin sprays offer a painless alternative for regulating blood glucose levels, providing a convenient option by allowing doses to be sprayed directly into the mouth. For example, NiedlFree Technologies introduced Ozulin, an oral insulin spray, in November 2023. Ozulin aims to offer a user-friendly solution for individuals with diabetes, especially those who may struggle with traditional injectable insulin methods. If approved, Ozulin could revolutionize diabetes management by offering a more convenient and pain-free alternative to insulin injections.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition merges Abbott's proficiency in continuous glucose monitoring with Bigfoot's smart insulin management systems, bolstering Abbott's standing as a leader in comprehensive diabetes care. The acquisition aligns with Abbott's dedication to advancing connected solutions for precise diabetes management. Bigfoot Biomedical Inc., a US-based medical technology company, specializes in intelligent insulin administration systems for diabetes care.

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

North America was the largest region in the non-injectable insulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-injectable insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-injectable insulin market consists of sales of oral insulin, inhaled insulin, nasal insulin, carrier agents, and stabilizers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-injectable Insulin Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-injectable insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-injectable insulin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-injectable insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Synthetic Insulin; Semi Synthetic Insulin
  • 2) By Product: Pills; Sprays; Other Products
  • 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Drug Stores
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Injectable Insulin Market Characteristics

3. Non-Injectable Insulin Market Trends And Strategies

4. Non-Injectable Insulin Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Non-Injectable Insulin Market Size and Growth

  • 5.1. Global Non-Injectable Insulin Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Non-Injectable Insulin Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Non-Injectable Insulin Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Injectable Insulin Market Segmentation

  • 6.1. Global Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Synthetic Insulin
  • Semi Synthetic Insulin
  • 6.2. Global Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pills
  • Sprays
  • Other Products
  • 6.3. Global Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Drug Stores

7. Non-Injectable Insulin Market Regional And Country Analysis

  • 7.1. Global Non-Injectable Insulin Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Non-Injectable Insulin Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Injectable Insulin Market

  • 8.1. Asia-Pacific Non-Injectable Insulin Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Injectable Insulin Market

  • 9.1. China Non-Injectable Insulin Market Overview
  • 9.2. China Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Injectable Insulin Market

  • 10.1. India Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Injectable Insulin Market

  • 11.1. Japan Non-Injectable Insulin Market Overview
  • 11.2. Japan Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Injectable Insulin Market

  • 12.1. Australia Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Injectable Insulin Market

  • 13.1. Indonesia Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Injectable Insulin Market

  • 14.1. South Korea Non-Injectable Insulin Market Overview
  • 14.2. South Korea Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Injectable Insulin Market

  • 15.1. Western Europe Non-Injectable Insulin Market Overview
  • 15.2. Western Europe Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Injectable Insulin Market

  • 16.1. UK Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Injectable Insulin Market

  • 17.1. Germany Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Injectable Insulin Market

  • 18.1. France Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Injectable Insulin Market

  • 19.1. Italy Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Injectable Insulin Market

  • 20.1. Spain Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Injectable Insulin Market

  • 21.1. Eastern Europe Non-Injectable Insulin Market Overview
  • 21.2. Eastern Europe Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Injectable Insulin Market

  • 22.1. Russia Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Injectable Insulin Market

  • 23.1. North America Non-Injectable Insulin Market Overview
  • 23.2. North America Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Injectable Insulin Market

  • 24.1. USA Non-Injectable Insulin Market Overview
  • 24.2. USA Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Injectable Insulin Market

  • 25.1. Canada Non-Injectable Insulin Market Overview
  • 25.2. Canada Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Injectable Insulin Market

  • 26.1. South America Non-Injectable Insulin Market Overview
  • 26.2. South America Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Injectable Insulin Market

  • 27.1. Brazil Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Injectable Insulin Market

  • 28.1. Middle East Non-Injectable Insulin Market Overview
  • 28.2. Middle East Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Injectable Insulin Market

  • 29.1. Africa Non-Injectable Insulin Market Overview
  • 29.2. Africa Non-Injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Non-Injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Non-Injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Injectable Insulin Market Competitive Landscape And Company Profiles

  • 30.1. Non-Injectable Insulin Market Competitive Landscape
  • 30.2. Non-Injectable Insulin Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Non-Injectable Insulin Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca
  • 31.4. Abbott Laboratories
  • 31.5. GlaxoSmithKline
  • 31.6. Takeda Pharmaceutical
  • 31.7. Eli Lilly and Company
  • 31.8. Boehringer Ingelheim
  • 31.9. Novo Nordisk A/S
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Mylan N.V.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Ipsen S.A.
  • 31.14. Cadila Healthcare Limited
  • 31.15. Dr. Reddy's Laboratories Limited

32. Global Non-Injectable Insulin Market Competitive Benchmarking

33. Global Non-Injectable Insulin Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Injectable Insulin Market

35. Non-Injectable Insulin Market Future Outlook and Potential Analysis

  • 35.1 Non-Injectable Insulin Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Non-Injectable Insulin Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Non-Injectable Insulin Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer